1. Home
  2. VRTX vs SAN Comparison

VRTX vs SAN Comparison

Compare VRTX & SAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • SAN
  • Stock Information
  • Founded
  • VRTX 1989
  • SAN 1857
  • Country
  • VRTX United States
  • SAN Spain
  • Employees
  • VRTX N/A
  • SAN N/A
  • Industry
  • VRTX EDP Services
  • SAN Commercial Banks
  • Sector
  • VRTX Technology
  • SAN Finance
  • Exchange
  • VRTX Nasdaq
  • SAN Nasdaq
  • Market Cap
  • VRTX 104.8B
  • SAN 92.1B
  • IPO Year
  • VRTX 1991
  • SAN 1987
  • Fundamental
  • Price
  • VRTX $484.74
  • SAN $6.78
  • Analyst Decision
  • VRTX Buy
  • SAN
  • Analyst Count
  • VRTX 25
  • SAN 0
  • Target Price
  • VRTX $508.09
  • SAN N/A
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • SAN 5.9M
  • Earning Date
  • VRTX 05-05-2025
  • SAN 04-30-2025
  • Dividend Yield
  • VRTX N/A
  • SAN 3.02%
  • EPS Growth
  • VRTX N/A
  • SAN 17.97
  • EPS
  • VRTX N/A
  • SAN 0.80
  • Revenue
  • VRTX $11,020,100,000.00
  • SAN $52,590,330,278.00
  • Revenue This Year
  • VRTX $10.65
  • SAN $23.26
  • Revenue Next Year
  • VRTX $9.02
  • SAN $3.02
  • P/E Ratio
  • VRTX N/A
  • SAN $8.53
  • Revenue Growth
  • VRTX 11.66
  • SAN 10.97
  • 52 Week Low
  • VRTX $377.85
  • SAN $4.27
  • 52 Week High
  • VRTX $519.88
  • SAN $7.16
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 44.78
  • SAN 55.99
  • Support Level
  • VRTX $471.50
  • SAN $6.58
  • Resistance Level
  • VRTX $513.98
  • SAN $7.12
  • Average True Range (ATR)
  • VRTX 12.35
  • SAN 0.11
  • MACD
  • VRTX -4.12
  • SAN -0.06
  • Stochastic Oscillator
  • VRTX 27.48
  • SAN 48.65

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About SAN Banco Santander S.A. Sponsored ADR (Spain)

Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.

Share on Social Networks: